2ONE Labs Prevails in Trademark Dispute against IMB Zone Brand

Business by 2FIRSTS.ai

Dec.24.2024

US nicotine pouch brand 2ONE Labs wins preliminary injunction in trademark dispute with Imperial Tobacco's Zone brand.

On December 23rd, the American nicotine pouch brand 2ONE Labs announced on its official website that the brand, in partnership with distributor Performance Plus Marketing, had achieved a favorable preliminary injunction (PI) ruling in a trademark dispute with the Imperial Tobacco brand Zone. According to a court order dated December 20th, 2024, Zone's nicotine pouches are prohibited from being shipped to trade partners in the United States.

The CEO of 2ONE Labs, Vincent Schuman, stated that

This ruling is significant as it prohibits Imperial Tobacco from continuing to sell Zone nicotine pouches in the United States until the ongoing 2ONE trademark lawsuit is resolved.

According to the judge's ruling, the defendant (Imperial) is prohibited from selling oral nicotine products with the Bullseye trademark or any similar symbol. (Case number: CV 24-08124-MWF(Ex) Title: 2ONE Labs Inc. et al v. ITG Brands, LLC et al)

We are pleased that the court has made the correct decision to approve this PI. This is an extraordinary remedy for 2ONE and sets the foundation for their victory in the trademark infringement lawsuit against Imperial Tobacco.

References:

[1] 2ONE Labs, Inc. Secures Federal Preliminary Injunction Against ITG Brands and Affiliates in Trademark Infringement Case

Also Read:

[1] 2ONE Labs Announces PMTA Submission Update, Nicotine Pouch Products Receive FDA 'Acceptance' Again

[2] U.S. nicotine pouch brand 2ONE Labs says 2ONE® gains FDA “approval”

[3] Lawsuit Filed Against Imperial Brands Over Trademark Infringement

#North America #United States #Legislation #Nicotine pouches

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency

The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.

Dec.02 by 2FIRSTS.ai

U.S. Lawmakers Seek to Empower HHS to Destroy Counterfeit Chinese Tobacco Products

Bipartisan members of the U.S. Congress have introduced the “Ensuring the Necessary Destruction of Illicit Chinese Tobacco Act” (END Act), seeking to amend the Federal Food, Drug, and Cosmetic Act to authorize the Department of Health and Human Services (HHS) to directly destroy adulterated, misbranded, or counterfeit imported tobacco products.Major tobacco companies, including Altria, along with several public health organizations, have announced their support for the bill.

Nov.11 by 2FIRSTS.ai

Azerbaijan Parliament Passes E-cigarette Ban Bill in First Reading

Azerbaijan’s Milli Majlis has approved, in its first reading, a bill that would ban the import, export, production, storage, wholesale and retail sale, and use of electronic cigarettes and their components. The bill amends the Law on Tobacco and Tobacco Products, classifying nicotine-containing e-cigarettes as tobacco products while explicitly excluding heated tobacco products. If adopted, the law would take effect on February 1, 2026.

Dec.22 by 2FIRSTS.ai

Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours

The U.S. FDA has added six ON!® PLUS nicotine pouch products to its list of Marketing Granted Order (MGO) authorizations. Based on 2Firsts’ review, the approved products feature a highly standardized configuration in terms of format, nicotine strength, and flavour portfolio, primarily focusing on 6 mg and 9 mg strengths and traditional variants such as mint, wintergreen, and tobacco—reflecting a clear compliance-oriented approach.